US Savings Top $338bn In 2020
As Savings Figure Linked To Biosimilars More Than Trebles To $7.9bn
Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.
You may also be interested in...
Following the publication of a real-world case-study of levothyroxine use that included switching between different versions of the product, the FDA has suggested that “institutional resistance” to generics – including from American Thyroid Association guidance that warns against switching – “may not be supported by real-world evidence.”
The National Alliance of Healthcare Purchaser Coalitions has worked with seven regional organizations and over 60 employers to identify five areas where US employers can take specific actions to expand access to biosimilars.
Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.